Monday, December 12, 2016 12:36:40 AM
It's an interesting idea, I just don't see it as being very likely.
If they sold out in the teens, it would be a huge loss for nearly anyone who invested here, as all their public offerings have been at higher prices. With approval of the drug, they would realistically be valued in the billions, and the current market cap here is well below that.
What it looks like to me, is that they're about to offer up some more stock for sale. Did you see the S3 and following notice of effectiveness?
Not sure exactly how or why, but it ALWAYS seems like stocks magically run right before a company is about to dump some more stock and dilute. Sometimes they do this to coincide with good news. In this case, I think they need more money to fully fund all the extra trials they needed to get the approval of eravacycline.
https://www.sec.gov/Archives/edgar/data/1373707/000119312516778155/d278406ds3a.htm
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM